Sequent Scientific Limited, which has businesses across Animal Health (Alivira) & Analytical Services today announced its financial results for the period ended March 31, 2021, on Wednesday.
The company’s revenues increased 20.4% to Rs361.8cr in the fourth quarter ended March 31, 2021, compared to Rs300.6cr during the same quarter last year. FY21 revenues grew 15.5% yoy to Rs1,361.6cr compared to Rs1,179.2cr in FY20.
Operating EBITDA at Rs61.1cr in Q4FY21, a growth of 19.5% yoy compared to Rs51.1cr in Q4FY20. Quarterly EBITDA Margin showed de-growth of 10bps to 16.9%. Yearly Operating EBITDA increased 35% yoy to Rs237.5cr compared to Rs175.8cr in FY20. Yearly EBITDA Margin increased 250bps to 17.4%.
Profit After Tax (PAT) in Q4FY21 rose 22.4% yoy to Rs20.6cr compared to Rs16.9cr in Q4FY20. Quarterly PAT margin lowered 40bps to 5.7%. Yearly PAT increased 36.5% yoy to Rs95.4cr compared to Rs69.9cr in FY20. Yearly PAT Margin increased 110bps to 7%.
“We are pleased to report another strong year of performance in an operationally challenging pandemic year. Our global formulations drove growth and strong outperformance in the key markets of Brazil, Turkey, and India,” Manish Gupta, Managing Director, stated.
“Revenue grew by 15.5% yoy to Rs13,616 Mn. Operating EBITDA increased to Rs2,375 Mn at 17.4%, a healthy expansion of 250 bps yoy. PAT grew 36.5% and the business generated Rs1.5 Bn+ in cash from operations enabling us to pare down debt, resulting in a two-notch improvement in credit rating. ROCE now exceeds 20%, reflecting the underlying strength of our business model we have built in Sequent 1.0. This confidence also reflects in the Board recommending a 25% dividend for the year,” Manish Gupta added.
At around 11.48 AM, Sequent Scientific Ltd was trading at Rs290.15 per piece down Rs22.50 or 7.20% from its previous closing of Rs312.65 per piece on the BSE.